Exploiting Fatty Acid Metabolism To Cure Malaria

利用脂肪酸代谢来治疗疟疾

• 批准号: 7764167
• 负责人: David A Fidock
• 金额: $ 40.1万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-23 至 2014-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7764167
• 关键词: Antimalarials; Artemisinins; Attenuated; Biochemical Pathway; Biology; Blood; Classification; Collaborations; Combined Modality Therapy; Dependency; Development; Disease; Drug usage; Falciparum Malaria; Fatty Acids; Gene Combinations; Generations; Genes; Growth; Immune response; Immunity; In Vitro; Infection; Investigation; Liver; Malaria; Measurable; Medicine; Methods; Modeling; Modification; Nutrient; Parasites; Parasitic Diseases; Pharmaceutical Preparations; Plasmodium; Plasmodium falciparum; Primates; Process; Prophylactic treatment; Recombinants; Reporting; Resistance; Rodent; Staging; Translating; Vaccines; artemisinine; asexual; base; combat; fatty acid metabolism; high reward; high risk; in vivo; industry partner; inhibitor/antagonist; killings; multidisciplinary; novel; novel strategies; pre-clinical; prevent; prophylactic; public health relevance; success; tool

DESCRIPTION (provided by applicant): The success of artemisinin-based combination therapies in combating Plasmodium falciparum malaria has inspired calls for the eradication of this devastating parasitic disease. However, new reports of emerging artemisinin resistance, and the absence of alternative first-line drugs, highlight an urgent need for new control methods. We propose a bold new plan to develop a new generation of antimalarial vaccines and drugs using a multidisciplinary, collaborative approach to exploit one particular biochemical pathway in the parasite lifecycle. Most currently available antimalarials target the symptomatic blood stage parasites rather than the initial asymptomatic liver stage, while many vaccine efforts have focused on recombinant subunit-based approaches. We are proposing a completely different approach based on our recent discovery that liver and blood stage parasites differ fundamentally in their fatty acid biology. In the rodent parasite P. berghei, deletion of the fabI gene, involved in de novo type II fatty acid synthesis (FAS-II), had no measurable effect on blood stage parasite growth, indicating that this stage depends on the import and modification of host fatty acids for intracellular replication. In contrast, the disruption of the fabI gene severely compromised the ability of the liver stage parasites to complete their development and initiate blood stage infection. In the related rodent species P. yoelii, deletion of the FAS-II gene fabB/F produced parasites that never completed their liver stage development. These attenuated parasites elicited robust protective immunity against infectious parasite challenge. Based on these findings, we hypothesize that parasite stage-specific differences in fatty acid metabolism can be uniquely exploited to develop effective antimalarial vaccines and drugs. We will implement a systematic approach to identifying combinations of genes involved in fatty acid metabolism and related processes, which when deleted can cause a total arrest of parasite liver stage development and elicit a robust and fully protective immune response. Successful P. berghei vaccines will be translated into P. falciparum to initiate preclinical assessments, in collaboration with Sanaria. We also define an experimental approach to evaluate a panel of FAS-II inhibitors, available from GlaxoSmithKline, for their ability to block liver stage development in vitro and in vivo. If potent and pharmacologically suitable inhibitors are found, these will be evaluated in a primate malaria prophylaxis model. Finally, our investigations of parasite mechanisms of import and modification of host fatty acids during asexual blood stage replication will validate the key effectors and guide the development of screens for curative agents that kill Plasmodium blood stages by starving them of essential host nutrients. This "high risk/high reward" project is based on a collaborative effort between academic groups and industry partners that can rapidly translate experimental discoveries into preclinical assessment. The successful discovery of new interventional tools arising from this project has the exciting potential to fundamentally transform the way in which malaria is prevented and controlled. ) PUBLIC HEALTH RELEVANCE: This Transformative R01 application proposes an entirely novel approach to developing vaccines and drugs to prevent malaria, based on our recent discovery of a fundamental difference in the way parasites replicating at the liver versus the blood stage acquire their fatty acids during intracellular growth. Exploiting the dependency of fatty acid synthesis by liver stage parasites, we propose to develop fatty acid synthesis-deficient, genetically attenuated parasite vaccines that arrest in the liver, causing a host immune response that protects against infectious challenge. In addition, we propose to target parasite synthesis as well as salvage of host fatty acids, as a means to develop novel prophylactic and curative medicines that can prevent and control this widespread and devastating disease.

描述(由申请人提供)：以青蒿素为基础的联合疗法在抗击恶性疟疾方面的成功促使人们呼吁根除这种毁灭性的寄生虫病。然而，关于出现青蒿素耐药性的新报告以及缺乏替代一线药物，突显了迫切需要新的控制方法。我们提出了一项大胆的新计划，利用多学科、协作的方法开发新一代抗疟疾疫苗和药物，以开发寄生虫生命周期中的一种特殊生化途径。目前可用的大多数抗疟药针对的是有症状的血液期寄生虫，而不是最初的无症状肝期，而许多疫苗努力集中在基于重组亚单位的方法上。基于我们最近的发现，我们提出了一种完全不同的方法，即肝脏和血液阶段的寄生虫在脂肪酸生物学上有根本的不同。在啮齿动物寄生虫P.berghei中，参与从头合成II型脂肪酸(Fas-II)的Fabi基因的缺失对血液期寄生虫的生长没有明显的影响，表明这一阶段依赖于宿主脂肪酸的输入和修饰以进行细胞内复制。相比之下，Fabi基因的破坏严重损害了肝期寄生虫完成发育和启动血期感染的能力。在相关的啮齿动物物种约氏P.yoelii中，Fas-II基因Fabb/F的缺失产生了从未完成肝期发育的寄生虫。这些减毒寄生虫对感染性寄生虫攻击产生了强大的保护性免疫。基于这些发现，我们假设可以独特地利用寄生虫阶段特定脂肪酸代谢的差异来开发有效的抗疟疾疫苗和药物。我们将实施一种系统的方法来识别参与脂肪酸代谢和相关过程的基因组合，当这些基因被删除时，可以导致寄生虫肝脏阶段的发育完全停止，并引发强大和完全保护性的免疫反应。与Sanaria合作，成功的伯氏疟原虫疫苗将被转化为恶性疟原虫，以启动临床前评估。我们还定义了一种实验方法来评估一组Fas-II抑制剂，这些药物可从葛兰素史克获得，用于评估它们在体外和体内阻止肝脏阶段发育的能力。如果找到了有效的和药理上合适的抑制剂，这些将在灵长类疟疾预防模型中进行评估。最后，我们对寄主脂肪酸在无性血期复制过程中输入和修饰寄主脂肪酸的寄生虫机制的研究将验证关键效应器，并指导通过饥饿必要的寄主营养来杀死血期疟原虫的治疗剂的开发。这个“高风险/高回报”的项目是基于学术团体和行业合作伙伴之间的合作努力，可以迅速将实验发现转化为临床前评估。该项目产生的新干预手段的成功发现具有从根本上改变疟疾预防和控制方式的令人振奋的潜力。) 与公共卫生相关：这一变革性的R01应用程序提出了一种全新的方法来开发预防疟疾的疫苗和药物，基于我们最近发现的寄生虫在肝脏和血液阶段复制的方式在细胞内生长期间获得脂肪酸的根本不同。利用肝期寄生虫对脂肪酸合成的依赖性，我们建议开发脂肪酸合成不足的、基因减毒的寄生虫疫苗，这些疫苗在肝脏中滞留，引起宿主免疫反应，保护免受感染挑战。此外，我们建议以寄生虫的合成和宿主脂肪酸的回收为目标，作为开发新的预防和治疗药物的手段，可以预防和控制这种广泛和毁灭性的疾病。